Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Eva Dombi"'
Autor:
Chelsea Kotch, Kristina Wagner, J. Harris Broad, Eva Dombi, Jane E. Minturn, Peter Phillips, Katherine Smith, Yimei Li, Ian N. Jacobs, Lisa M. Elden, Michael J. Fisher, Jean Belasco
Publikováno v:
Cancers, Vol 15, Iss 9, p 2621 (2023)
Limited therapies exist for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN). For this reason, the activity of vinblastine (VBL) and methotrexate (MTX) was evaluated in children and young adults with NF1 and PN. Patients ≤ 25 y
Externí odkaz:
https://doaj.org/article/b53aa07048db467aaef3d21864b29578
Autor:
Ravi A Madan, Christopher Heery, Claudia Palena, Caroline Jochems, Julius Strauss, Marijo Bilusic, Fatima Karzai, Jennifer L Marté, Charalampos Floudas, Peter J DeMaria, Katherine Lee-Wisdom, Angie Schwab, Jason Mark Redman, Eva Dombi, Brigitte Widemann, Borys Korchin, Tatiana Adams, Cesar Pico-Navarro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/37a0f2d29a6c47d6940c4dc1bf5400ca
Autor:
Brigitte C. Widemann, Yao Lu, Denise Reinke, Scott H. Okuno, Christian F. Meyer, Gregory M. Cote, Rashmi Chugh, Mohammed M. Milhem, Angela C. Hirbe, AeRang Kim, Brian Turpin, Joseph G. Pressey, Eva Dombi, Nalini Jayaprakash, Lee J. Helman, Ndidi Onwudiwe, Karen Cichowski, John P. Perentesis
Publikováno v:
Sarcoma, Vol 2019 (2019)
Purpose. There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease
Externí odkaz:
https://doaj.org/article/401c98540a2a455a8f01beecb09b82fe
Autor:
Jianqiang Wu, Vincent W. Keng, Deanna M. Patmore, Jed J. Kendall, Ami V. Patel, Edwin Jousma, Walter J. Jessen, Kwangmin Choi, Barbara R. Tschida, Kevin A.T. Silverstein, Danhua Fan, Eric B. Schwartz, James R. Fuchs, Yuanshu Zou, Mi-Ok Kim, Eva Dombi, David E. Levy, Gang Huang, Jose A. Cancelas, Anat O. Stemmer-Rachamimov, Robert J. Spinner, David A. Largaespada, Nancy Ratner
Publikováno v:
Cell Reports, Vol 14, Iss 8, Pp 1979-1990 (2016)
To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that becom
Externí odkaz:
https://doaj.org/article/b85859bc4dea43bd98344313076ad5bb
Autor:
Christine S. Higham, Seth M. Steinberg, Eva Dombi, Arie Perry, Lee J. Helman, Scott M. Schuetze, Joseph A. Ludwig, Arthur Staddon, Mohammed M. Milhem, Daniel Rushing, Robin L. Jones, Michael Livingston, Stewart Goldman, Christopher Moertel, Lars Wagner, David Janhofer, Christina M. Annunziata, Denise Reinke, Lauren Long, David Viskochil, Larry Baker, Brigitte C. Widemann
Publikováno v:
Sarcoma, Vol 2017 (2017)
Background. Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods. We evaluated the objective response (OR) rate of patients with A
Externí odkaz:
https://doaj.org/article/201204feb6c0442c98e1d96badf1ee06
Autor:
Catherine Lai, Diane E. Cole, Seth M. Steinberg, Nicole Lucas, Eva Dombi, Christopher Melani, Mark Roschewski, Frank Balis, Brigitte C. Widemann, Wyndham H. Wilson
Publikováno v:
Blood Advances. 7:529-532
Aggressive lymphomas are curable with doxorubicin-based chemotherapy. In patients presenting with elevated serum bilirubin, doxorubicin is commonly dose reduced or delayed based on limited pharmacokinetic data. We evaluated plasma pharmacokinetics of
Autor:
John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, John Shern, Seth M. Steinberg, William D. Figg, Cody J. Peer, Sara Zimmerman, Josquin Moraly, Xia Xu, Stephen Fox, King Chan, Michael I. Barbato, Thorkell Andresson, Naomi Taylor, Karel Pacak, J. Keith Killian, Eva Dombi, W. Marston Linehan, Markku Miettinen, Richard Piekarz, Lee J. Helman, Paul Meltzer, Brigitte Widemann, John Glod
Publikováno v:
Clinical Cancer Research. 29:341-348
Purpose: Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT
Autor:
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave, AeRang Kim, Laura J Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M Payne, Katherine A Rauen, Jonathan J Rios, Nathan Robison, Elizabeth K Schorry, Kevin Shannon, David A Stevenson, Elliot Stieglitz, Nicole J Ullrich, Karin S Walsh, Brian D Weiss, Pamela L Wolters, Kaleb Yohay, Marielle E Yohe, Brigitte C Widemann, Michael J Fisher
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 24, iss 11
Neuro-Oncology, vol 24, iss 11
The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent
Autor:
Mark Jackson, Niousha Ahmari, Jianqiang Wu, Tilat A. Rizvi, Elizabeth Fugate, Mi-OK Kim, Eva Dombi, Heribert Arnhof, Guido Boehmelt, Matthias J. Düchs, Clive J. Long, Udo Maier, Francesca Trapani, Marco H. Hofmann, Nancy Ratner
Publikováno v:
J Pharmacol Exp Ther
The Journal of pharmacology and experimental therapeutics, vol 385, iss 2
The Journal of pharmacology and experimental therapeutics, vol 385, iss 2
Individuals with neurofibromatosis type 1 develop rat sarcoma virus (RAS)–mitogen-activated protein kinase–mitogen-activated and extracellular signal-regulated kinase (RAS-MAPK-MEK)–driven nerve tumors called neurofibromas. Although MEK inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4586491f3a1471bd72362287987e00
https://europepmc.org/articles/PMC10108440/
https://europepmc.org/articles/PMC10108440/
Autor:
Andrea M Gross, Eva Dombi, Pamela L Wolters, Andrea Baldwin, Anne Dufek, Kailey Herrera, Staci Martin, Joanne Derdak, Kara S Heisey, Patricia M Whitcomb, Seth M Steinberg, David J Venzon, Michael J Fisher, AeRang Kim, Miriam Bornhorst, Brian D Weiss, Jaishri O Blakeley, Malcolm A Smith, Brigitte C Widemann
Publikováno v:
Neuro-Oncology.
Background Selumetinib shrank inoperable symptomatic plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) and provided clinical benefit for many in our previously published phase 1/2 clinical trials (SPRINT, NCT01362803). At t